Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 79

1.

Glioblastoma--a moving target.

Westermark B.

Ups J Med Sci. 2012 May;117(2):251-6. doi: 10.3109/03009734.2012.676574. Review.

2.

Cooperativity within and among Pten, p53, and Rb pathways induces high-grade astrocytoma in adult brain.

Chow LM, Endersby R, Zhu X, Rankin S, Qu C, Zhang J, Broniscer A, Ellison DW, Baker SJ.

Cancer Cell. 2011 Mar 8;19(3):305-16. doi: 10.1016/j.ccr.2011.01.039.

3.

Genetic biomarkers of drug response for small-molecule therapeutics targeting the RTK/Ras/PI3K, p53 or Rb pathway in glioblastoma.

Venkatesan S, Lamfers ML, Dirven CM, Leenstra S.

CNS Oncol. 2016;5(2):77-90. doi: 10.2217/cns-2015-0005. Epub 2016 Mar 17. Review. Erratum in: CNS Oncol. 2016 Jul;5(3):188.

4.

Network pharmacology of glioblastoma.

Aguda BD.

Curr Drug Discov Technol. 2013 Jun;10(2):125-38. Review.

PMID:
23237675
5.

ERK and PI3K signaling cascades induce Nrf2 activation and regulate cell viability partly through Nrf2 in human glioblastoma cells.

Cong ZX, Wang HD, Wang JW, Zhou Y, Pan H, Zhang DD, Zhu L.

Oncol Rep. 2013 Aug;30(2):715-22. doi: 10.3892/or.2013.2485. Epub 2013 May 23.

PMID:
23708697
6.

Receptor tyrosine kinase-Ras-PI 3 kinase-Akt signaling network in glioblastoma multiforme.

Tuncel G, Kalkan R.

Med Oncol. 2018 Aug 4;35(9):122. doi: 10.1007/s12032-018-1185-5. Review.

PMID:
30078108
7.

ROS fusion tyrosine kinase activates a SH2 domain-containing phosphatase-2/phosphatidylinositol 3-kinase/mammalian target of rapamycin signaling axis to form glioblastoma in mice.

Charest A, Wilker EW, McLaughlin ME, Lane K, Gowda R, Coven S, McMahon K, Kovach S, Feng Y, Yaffe MB, Jacks T, Housman D.

Cancer Res. 2006 Aug 1;66(15):7473-81.

8.

Co-occurrence of Wilson's disease and glioblastoma multiforme--is it a chance association?

Sinha S, Prashanth LK, Mahadevan A, Satish S, Ravishankar S, Arunodaya GR, Taly AB, Shankar SK.

Clin Neuropathol. 2004 Sep-Oct;23(5):241-4.

PMID:
15581028
9.

The clinicopathologic values of the molecules associated with the main pathogenesis of the glioblastoma.

Kim B, Myung JK, Seo JH, Park CK, Paek SH, Kim DG, Jung HW, Park SH.

J Neurol Sci. 2010 Jul 15;294(1-2):112-8. doi: 10.1016/j.jns.2010.03.019. Epub 2010 May 2.

PMID:
20441994
11.

Detection of p53 mutations in proliferating vascular cells in glioblastoma multiforme.

Kawasoe T, Takeshima H, Yamashita S, Mizuguchi S, Fukushima T, Yokogami K, Yamasaki K.

J Neurosurg. 2015 Feb;122(2):317-23. doi: 10.3171/2014.10.JNS132159. Epub 2014 Nov 21.

PMID:
25415071
12.

Antitumor activity of NVP-BKM120--a selective pan class I PI3 kinase inhibitor showed differential forms of cell death based on p53 status of glioma cells.

Koul D, Fu J, Shen R, LaFortune TA, Wang S, Tiao N, Kim YW, Liu JL, Ramnarian D, Yuan Y, Garcia-Echevrria C, Maira SM, Yung WK.

Clin Cancer Res. 2012 Jan 1;18(1):184-95. doi: 10.1158/1078-0432.CCR-11-1558. Epub 2011 Nov 7.

13.

p53 and Pten control neural and glioma stem/progenitor cell renewal and differentiation.

Zheng H, Ying H, Yan H, Kimmelman AC, Hiller DJ, Chen AJ, Perry SR, Tonon G, Chu GC, Ding Z, Stommel JM, Dunn KL, Wiedemeyer R, You MJ, Brennan C, Wang YA, Ligon KL, Wong WH, Chin L, DePinho RA.

Nature. 2008 Oct 23;455(7216):1129-33. doi: 10.1038/nature07443.

14.

PI3Kinase signaling in glioblastoma.

Lino MM, Merlo A.

J Neurooncol. 2011 Jul;103(3):417-27. doi: 10.1007/s11060-010-0442-z. Epub 2010 Nov 10. Review.

15.

Alterations of the p53 and pRB pathways in human astrocytoma.

Rutka JT, Akiyama Y, Lee SP, Ivanchuk S, Tsugu A, Hamel PA.

Brain Tumor Pathol. 2000;17(2):65-70. Review.

PMID:
11210173
16.

Yes and PI3K bind CD95 to signal invasion of glioblastoma.

Kleber S, Sancho-Martinez I, Wiestler B, Beisel A, Gieffers C, Hill O, Thiemann M, Mueller W, Sykora J, Kuhn A, Schreglmann N, Letellier E, Zuliani C, Klussmann S, Teodorczyk M, Gröne HJ, Ganten TM, Sültmann H, Tüttenberg J, von Deimling A, Regnier-Vigouroux A, Herold-Mende C, Martin-Villalba A.

Cancer Cell. 2008 Mar;13(3):235-48. doi: 10.1016/j.ccr.2008.02.003.

17.

Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution.

Kim H, Zheng S, Amini SS, Virk SM, Mikkelsen T, Brat DJ, Grimsby J, Sougnez C, Muller F, Hu J, Sloan AE, Cohen ML, Van Meir EG, Scarpace L, Laird PW, Weinstein JN, Lander ES, Gabriel S, Getz G, Meyerson M, Chin L, Barnholtz-Sloan JS, Verhaak RG.

Genome Res. 2015 Mar;25(3):316-27. doi: 10.1101/gr.180612.114. Epub 2015 Feb 3.

18.

p53 mutations versus EGF receptor expression in giant cell glioblastomas.

Peraud A, Watanabe K, Plate KH, Yonekawa Y, Kleihues P, Ohgaki H.

J Neuropathol Exp Neurol. 1997 Nov;56(11):1236-41.

PMID:
9370234
19.

Targeting strategies on miRNA-21 and PDCD4 for glioblastoma.

Wang G, Wang JJ, Tang HM, To SS.

Arch Biochem Biophys. 2015 Aug 15;580:64-74. doi: 10.1016/j.abb.2015.07.001. Epub 2015 Jul 2. Review.

PMID:
26142886
20.

The phosphoinositide 3-kinase signaling pathway as a therapeutic target in grade IV brain tumors.

Höland K, Salm F, Arcaro A.

Curr Cancer Drug Targets. 2011 Oct;11(8):894-918. Review.

PMID:
21861842

Supplemental Content

Support Center